Global /Taiwan /Healthcare /Drug Manufacturers - General /6541

Tanvex BioPharma, Inc.

6541

• TWSE: 6541 • Delayed

39.60TWD -0.4%

1.25 USD

As of 10 June 2026, Tanvex BioPharma, Inc. has a market cap of $333.59M USD, ranking #17913 globally and #696 in Taiwan. It ranks #1623 in the Healthcare sector, and #583 in the Drug Manufacturers - General industry.

Global Rank

17913

Country Rank

696

Sector Rank

1623

Industry Rank

583

Key Stats

Market Cap

$333.59MUSD

10.53B TWD

Enterprise Value

$355.76MUSD

11.23B TWD

Revenue (TTM)

$12.7MUSD

400.97M TWD

EBITDA (TTM)

-$39.46MUSD

-1.25B TWD

Net Income (TTM)

-$47.53MUSD

-1.5B TWD

PS Ratio

26.3

PB Ratio

1.8

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Stephen Lam open_in_new

Founded

2011

Website

tanvex.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.4%	-3.1%	-4.8%	-29%	-32%	-28%	-37%	-48%	-80%

News

Markets

Exchange	Ticker	Price	Quotes
Taiwan Stock Exchange (TWSE) MIC: XTAI PRIMARY	6541 Tanvex BioPharma Inc ISIN: KYG8676P1037 Shares Out.: Shares Outstanding: 264.986M¹ Shares Float: 171.829M² TV: TradingView: TWSE: 6541 SA: Stock Analysis: TPE: 6541 YF: Yahoo Finance: 6541.TW GF: Google Finance: TPE: 6541 BA: Barron's: 6541 MS: Morningstar: XTAI: 6541	39.60 TWD	TV: TradingView: TWSE: 6541 SA: Stock Analysis: TPE: 6541 YF: Yahoo Finance: 6541.TW GF: Google Finance: TPE: 6541 BA: Barron's: 6541 MS: Morningstar: XTAI: 6541

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.

Similar Companies

Industry: Drug Manufacturers - General (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
PharmaEssentia Corp. TWSE: 6446	$7.77B 245.34B TWD 2K%	48.6	Taiwan
Lotus Pharmaceutical Co., Ltd. TWSE: 1795	$1.84B 57.95B TWD 450%	12.2	Taiwan
Center Laboratories, Inc. TPEX: 4123	$922.51M 29.11B TWD 177%	3.4	Taiwan
Lumosa Therapeutics Co., Ltd. TPEX: 6535	$806.64M 25.46B TWD 142%	-	Taiwan
Oneness Biotech Co., Ltd. TPEX: 4743	$786.54M 24.82B TWD 136%	-	Taiwan
TTY Biopharm Company Ltd. TPEX: 4105	$582.23M 18.38B TWD 75%	11.8	Taiwan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 228K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 164K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 108K%	97.4	United States
Roche Holding AG SIX: RO	$321.17B 256.25B CHF 96K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$287.57B 215.59B GBP 86K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.35B 218.9B CHF 82K%	20.5	Switzerland

chevron_leftBack